About US
Contact us
-
Amygdala Neurosciences to acquire GS-6637 from Gilead SciencesUS-based Amygdala Neurosciences has signed an agreement to acquire GS-6637, a ALDH2 inhibitor from Gilead Sciences. GS-6637 is a Phase II ready compound with the potential to treat behaviour and subs2017/2/21
-
Japan’s Takeda acquires US cancer drug manufacturer ARIAD for $5.2bnJapan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn. The acquisition was concluded through a ten2017/2/21
-
ALK receives acceptance for ragweed sublingual allergy immunotherapy tabletDanish-based pharmaceutical company ALK’s European regulatory filing for its ragweed sublingual allergy immunotherapy (SLIT) tablet has received acceptance from the relevant health authorities. The f2017/2/20
-
Vedanta, Stanford and Leiden universities partner to study food allergies in childrenUS-based Vedanta Biosciences has collaborated with Stanford University School of Medicine and Leiden University Medical Center to study food allergies in children and patients with C difficile infecti2017/2/20
-
Sanofi, Novo and Lilly face class action over 'astounding' insulin price hikesAn “insidious” pricing war has left patients with huge, “devastating” bills for their needed insulins, according to a new class actionlawsuitfiled against Sanofi, Novo Nordisk and Eli Lilly. The plai2017/2/17
-
Mylan faces FTC antitrust probe over generic-thwarting EpiPen tweaksMylan’s EpiPen saga isn’t over. After a series of Congressionaldemandsand hearings, back-and-forth with government officials, and a tentative settlement with the Justice Department over Medicaid overc2017/2/17
-
AZ nabs 6 more months of Symbicort exclusivity—and the sales that come with itAstraZeneca’s aging respiratory giant Symbicort won a coveted pediatric exclusivity nod from the FDA on Wednesday, giving the brand a longer life—and potentially hundreds of millions in additional sal2017/2/16
-
Teva faces billions in lost sales as court tosses four long-acting Copaxone patentsIt’s déjà vu for Teva Pharmaceutical in a bad, bad way. Late Monday, the Israeli drugmakerconfirmedthat the U.S. District Court for the District of Delaware had upturned four of its patents on the lo2017/2/16
-
Inherited pay-for-delay penalties are getting expensive for 'cash-strapped' TevaTeva is eager to start moving in the right direction after a particularly rocky 2016. Problem is, it’s still paying for pay-for-delay decisions made by its products’ previous owners. Both Paul Bisaro2017/2/15
-
Sandoz head: Enbrel biosimilar Erelzi won't launch before 2018, delayed by legal battleNovartis CEO Joe Jimenez today pointed to the company’s biosimilars program as being one buffer if President Trump’s threat to cut drug prices should materialize into some action. The drugmaker has tw2017/2/15